Floatz logo

Ciprofloxacin

Cyclophosphamide

National Cancer Institute (NCI)Small moleculePhase 3Dormant
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Cyclophosphamide cohort.

Asset / SponsorPhaseRating
Inno-206
Second Affiliated Hospital of Soochow University
Phase 3BB
FILGRASTIM
Second Affiliated Hospital of Soochow University
Phase 3BB
Cyclophosphamide
Second Affiliated Hospital of Soochow University
Phase 3BB
TAMOXIFEN
National Cancer Institute (NCI)
Phase 3BB
PREDNISONE TABLETS
Second Affiliated Hospital of Soochow University
Phase 2CCC

View all 11 →

Same molecule, other indications

Ciprofloxacin is also rated in:

bronchiectasisDormant
BBB
Indicative ·
76 / 100
View asset →
infectious diseaseDormant
BBB
Indicative ·
72 / 100
View asset →
chronic obstructive pulmonary diseaseDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →